Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Anticancer Research

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 20682976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC.

  2010cited by this paper
• Epithelial–mesenchymal transition in cancer development and its clinical significance

  2010cited by this paper
• Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

  2010cited by this paper
• Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status

  2010cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.

  2009cited by this paper
• E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.

  2008cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

  2007cited by this paper
• The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma

  2006cited by this paper
• Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.

  2006cited by this paper
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

  2006cited by this paper
• The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.

  2006cited by this paper
• Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.

  2006cited by this paper
• Resistance to gefitinib

  2006cited by this paper
• 100 years of lung cancer.

  2006cited by this paper
• Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

  2006cited by this paper
• Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

  2005cited by this paper
• E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases

  2004cited by this paper
• Epithelial–mesenchymal transitions in tumour progression

  2002cited by this paper
• High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper

• JAB-3312, a Potent Allosteric SHP2 Inhibitor that Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.

  2025cites this paper
• Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

  2025cites this paper
• Response and Resistance to RAS Inhibition in Cancer.

  2025cites this paper
• Targeting epithelial-mesenchymal transition signaling pathways with Dietary Phytocompounds and repurposed drug combinations for overcoming drug resistance in various cancers

  2025cites this paper
• NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.

  2025cites this paper
• The activity of EGFR CAR-NK and CAR-T cells against EGFR inhibitor-resistant NSCLC and drug-tolerant persister cells.

  2025cites this paper
• Cancer resistance and metastasis are maintained through oxidative phosphorylation.

  2024cites this paper
• Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)

  2024cites this paper
• Cancer Stem Cells in Carcinogenesis and Potential Role in Pancreatic Cancer.

  2023cites this paper
• Design of siRNA Bioconjugates for Efficient Control of Cancer-Associated Membrane Receptors

  2023cites this paper
• Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance

  2023cites this paper
• CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.

  2023cites this paper
• DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status

  2023cites this paper
• Significance of culture period on the physiochemistry and anti-cancer potentials of polysaccharides from mycelia of Ganoderma lucidum.

  2023cites this paper
• Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Chemotherapy in Acute Myeloid Leukemia

  2023cites this paper
• The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition

  2022cites this paper
• Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma

  2022cites this paper
• Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells

  2022cites this paper
• TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer

  2022cites this paper
• EGFR signaling pathway as therapeutic target in human cancers.

  2022cites this paper
• Epithelial–Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress

  2022cites this paper
• Ferroptosis: regulation by competition between NRF2 and BACH1 and propagation of the death signal

  2022cites this paper
• SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.

  2021cites this paper
• DEHP mediates drug resistance by directly targeting AhR in human breast cancer.

  2021cites this paper
• Extracellular Vesicles and Cancer Stem Cells in Tumor Progression: New Therapeutic Perspectives

  2021cites this paper
• Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

  2021cites this paper
• Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations

  2021cites this paper
• Identifying transcriptional programs underlying cancer drug response with TraCe-seq

  2021cites this paper
• Lineage Plasticity in Cancer: The Tale of a Skin-Walker

  2021cites this paper
• Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial–mesenchymal transition process

  2021cites this paper
• FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.

  2021cites this paper
• Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors.

  2020cites this paper
• Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

  2020cites this paper
• Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer

  2020cites this paper
• FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway.

  2020cites this paper
• Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer

  2020influential citation
• Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

  2020cites this paper
• Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer

  2020cites this paper
• Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer

  2020cites this paper
• Zoledronic acid re-sensitises gefitinib-resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial-mesenchymal transition

  2020cites this paper
• Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

  2020cites this paper
• FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

  2020cites this paper
• Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib.

  2020cites this paper
• Molecular Profiling of Afatinib-Resistant Non-Small Cell Lung Cancer Cells in vivo Derived from Mice.

  2020cites this paper
• Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial–mesenchymal transition through targeting major vault protein (MVP)

  2020influential citation
• A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

  2020cites this paper
• Astragalus polysaccharides reverse gefitinib resistance by inhibiting mesenchymal transformation in lung adenocarcinoma cells.

  2020influential citation
• Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.

  2019cites this paper
• A Genetic Interaction Analysis Identifies Novel Cancer Driver Modifiers and a Combination Therapy

  2019cites this paper
• Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

  2019cites this paper
• Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

  2019cites this paper
• CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.

  2019cites this paper
• Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.

  2019cites this paper
• Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon

  2019cites this paper
• Engineering Multidimensional Evolutionary Forces to Combat Cancer.

  2019cites this paper
• A sulfated glucan from Antrodia cinnamomea reduces Slug expression through regulation of TGFβ/AKT/GSK3β axis in lung cancer.

  2019cites this paper
• Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

  2018cites this paper
• The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance

  2018cites this paper
• Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.

  2018cites this paper
• Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non‐Small Cell Lung Cancer: The Role of Cancer Stem Cells

  2018cites this paper
• The regulatory role of APE1 in epithelial‐to‐mesenchymal transition and in determining EGFR‐TKI responsiveness in non‐small‐cell lung cancer

  2018cites this paper
• Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells.

  2018cites this paper
• Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil

  2018cites this paper
• MET amplification increases the metastatic spread of EGFR-mutated NSCLC.

  2018cites this paper
• Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer.

  2018cites this paper
• Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression

  2018cites this paper
• RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma

  2018cites this paper
• Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

  2018cites this paper
• miR‐1‐3p and miR‐206 sensitizes HGF‐induced gefitinib‐resistant human lung cancer cells through inhibition of c‐Met signalling and EMT

  2018cites this paper
• Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.

  2018cites this paper
• The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer

  2017cites this paper
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

  2017cites this paper
• TGF&bgr; pathway inhibition in the treatment of non‐small cell lung cancer

  2017cites this paper
• Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers

  2017cites this paper
• Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial‐mesenchymal transition in a lung adenocarcinoma patient with EGFR‐TKI drug resistance

  2017cites this paper
• Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor‐β receptor I in head and neck cancer

  2017cites this paper
• Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.

  2017cites this paper
• Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition.

  2017cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC

  2017cites this paper
• Dual strands of pre-miR‑150 (miR‑150‑5p and miR‑150‑3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer.

  2017cites this paper
• Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes

  2017cites this paper
• CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma

  2017cites this paper
• The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer

  2017cites this paper
• Managing Resistance to EFGR- and ALK-Targeted Therapies.

  2017cites this paper
• A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition

  2017cites this paper
• A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

  2017cites this paper
• Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment

  2016cites this paper
• Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT.

  2016cites this paper
• Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations

  2016cites this paper
• The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment

  2016cites this paper
• Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

  2016influential citation
• Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors

  2016cites this paper
• Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance

  2016cites this paper
• Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition

  2016cites this paper
• Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.

  2016cites this paper
• Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.

  2016cites this paper
• The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.

  2016cites this paper
• Nano-biomechanical Validation of Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinomas.

  2016cites this paper
• Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies.

  2016cites this paper